Colchicine repurposing for myh7-associated dilated cardiomyopathy treatment
A novel approach to treat MYH7-associated dilated cardiomyopathy by restoring the MEF2C-desmin signaling axis or using colchicine to improve cardiomyocyte contractility. This utilizes an FDA-approved drug, offering a rapid therapeutic solution.
Overview
This research focuses on addressing MYH7-associated dilated cardiomyopathy (DCM) by targeting the underlying molecular mechanism involving the MEF2C-desmin (DES) signaling axis. The study proposes the use of colchicine, an FDA-approved medication, to improve the contractility of patient-specific cardiomyocytes affected by MYH7 mutations. This innovative approach could significantly enhance treatment options for DCM by leveraging existing pharmacological agents.
Technical specifications
- Core mechanism: MYH7 mutations suppress the MEF2C-DES axis, leading to DNA damage and reduced contractility in cardiomyocytes.
- Solution approach: Restoration of the MEF2C-DES axis or blockade of downstream DNA damage using colchicine.
- Validation methods: Use of gene-edited human induced pluripotent stem cell-derived cardiomyocytes (hiPSC-CMs) and adeno-associated virus for desmin restoration.
- Testing and measurement: Employing traction force microscopy and engineered heart tissues to measure contractile function improvements.
Technology readiness level
The research is at Technology Readiness Level 6, having demonstrated proof of concept and initial validation in laboratory settings with human induced pluripotent stem cells and myocardial samples.
About University of Washington
The University of Washington is a large public research university with campuses in Seattle, Bothell, and Tacoma, known for a broad portfolio from fundamental discovery to applied innovation. Industry partners engage through a South Lake Union research campus adjacent to a major life sciences district and through collaboration programs that place faculty and students alongside corporate R&D. The university’s integration with a major academic health system enables clinical translation and large-scale trials. Research is supported by competitive federal funding from NIH, NSF, DOE, and DoD. A dedicated technology transfer office manages IP, licensing, and startup incubation with prototyping resources.
delivered to your inbox.